VB
Vikas Bhardwaj
Medical Technologist, AIIMS New Delhi
Updated: Apr 17, 2026
**Core Concept**
The patient's presentation, including easy bruising, frequent headaches, and splenomegaly, suggests a diagnosis of Essential Thrombocythemia (ET), a myeloproliferative disorder characterized by excessive platelet production. The normal leukocyte count and platelet count, along with a normal leukocyte alkaline phosphatase score, support this diagnosis.
**Why the Correct Answer is Right**
The drug of choice for ET is anagrelide, a selective inhibitor of platelet aggregation that acts by inhibiting the production of platelets in the bone marrow. Anagrelide is most effective when used to reduce the platelet count to a safe range, thereby reducing the risk of thrombotic complications. This is particularly important in patients with ET, as they are at increased risk of developing thrombotic events due to their elevated platelet count.
**Why Each Wrong Option is Incorrect**
**Option A:** Hydroxyurea is a chemotherapeutic agent that can be used to reduce platelet production, but it is not the first-line treatment for ET and can have significant side effects.
**Option B:** Interferon-alpha is used to treat some myeloproliferative disorders, but it is not the preferred treatment for ET due to its side effects and the availability of more effective and safer alternatives.
**Option C:** Aspirin may be used to reduce the risk of thrombotic events in patients with ET, but it is not a treatment for the underlying condition and does not address the elevated platelet count.
**Clinical Pearl / High-Yield Fact**
In patients with ET, the goal of treatment is to reduce the platelet count to a safe range, thereby reducing the risk of thrombotic complications. Anagrelide is a highly effective and relatively safe option for achieving this goal.
**Correct Answer:** C. Anagrelide